How could this recognition shape future research or innovation in immunology? | DW News

Scientists won the Nobel Prize
12 followers
5 Video Views·Jan 9, 2026
AI Generated·May contain errors
This year's Nobel Medicine Prize has been awarded
to three scientists for their work
on the human immune system.
The award goes to Americans Mary Brunco and Fred Ramsdale
and Japan's Shimon Sakaguchi, who told reporters
that the honor came as a surprise.
Their research looked at how the immune system
fights invaders like bacteria and viruses
without attacking the body's own cells.
Well, I'm joined now by Gunilla Carlsson-Hedestam,
professor of immunology and part of the Nobel Committee
of the Karolinska Institute in Stockholm, Sweden.
It's good to have you with us.
Tell us more about why you and the Nobel Committee,
why you selected Mary Brunco, Fred Ramsdale
and Shimon Sakaguchi for the prize.
Well, this trio broke some new ground
and they really worked out what is quite a complex principle
on how we recognize foreign versus self,
as you just explained.
And this is really not an easy feat
and it was a sort of a three-step process
where they each contributed critical discoveries.
So that is really what the Nobel Prize is all about
is making those groundbreaking discoveries
that lead then many other researchers to kind of build
and the field really expanded
after they made their discoveries.
Yeah, and what impact does their work have
on today's science?
I mean, we all know someone who has an autoimmune disease,
be it diabetes, multiple sclerosis, Crohn's disease.
So how can people who are sick today,
how can they hope to benefit from this?
So I think this is now a very, very active field
and there is in fact approximately 200 clinical trials
ongoing where clinicians and researchers are trying
to find ways to either expand the activity of these cells
or increase the activity of these regulatory cells
in diseases like autoimmune diseases
and also in some skin allergies, for example.
So there's actually many diseases
where there is potential for these treatments
to provide new sort of approaches to handle them.
And transplantation is of course also a classic example
of where you may want to control the immune system
and this is what these cells do.
They are basically programmed to control our immune system
so we don't respond too strongly to the wrong things.
Another really interesting and important area is cancer
and that is actually the opposite.
In those cases, you want to block the activity
of these cells to enhance immunity against the tumor.
So it really touches upon quite a lot of different diseases.
Was there a particular moment or breakthrough
in the research of this trio
that the committee found especially compelling?
Yes, I mean there's two parts to it really.
Sakaguchi did the first discoveries
and he was very, very persistent.
He had a notion.
He understood that there must be a type of T cell.
This is all about the white blood cells, the T cells.
And he understood that there must be a sort
of a guardian cell that ensures
that we don't respond to the wrong things.
So he worked in the 80s and the 90s
and eventually was able to show that these cells exist.
But the sort of critical evidence didn't come
until a few years later when Mary Branco
and Fred Ramstells were able
to actually show what genes control these cells.
And this together then really was sort
of nailed the discoveries and showed
that this is a very specific type of cell
that is programmed to dampen the immune response
in contrast to our other T cells that are there to attack.
But it's too dangerous to have an immune system
that doesn't have these checks and balances
because the immune system is very powerful.
So to characterize this extra layer
of the immune system was very important.
And once we understand that,
we can also then work towards using it.
Yeah, it's fascinating.
And we understand there is a woman among the three winners.
She's only the 14th woman out of 232 laureates
to get a Nobel in medicine.
What do we know about Mary Branco?
So this is actually a good question
because we did not know much in terms.
She has kept a fairly low profile.
She has not had a classic academic career.
She's working as a very distinguished staff scientist
at an institute in Seattle,
but not sort of having her own typical academic career.
And she's not a professor, et cetera,
but she did these extremely important findings.
And this is what she's awarded for.
And that is enough for a Nobel Prize.
It's exactly what Nobel Prizes are for,
is to pinpoint those very important breakthroughs
that allow other people to then expand
and build on that field.
So I would say this morning,
we didn't know much about Mary Branco.
Of course, we in the committee did
because we have researched everything that was done
from the very early days of this field,
but the world in general did not know much about her.
But I think that's all changed today
because I can see that she's already done
a lot of interviews during the day.
So it will be very exciting to hear what she has to say
when she comes to Stockholm in December.
It will be, for sure.
Gunilla Carlsson, Head of STEM,
we appreciate your time and your insights tonight.
We appreciate you taking the time to talk with us.
Thank you.
Thanks very much.
And joining me here at the big table now
is our science reporter, Matthew Ward-Ages.
Matthew, it's good to see you again.
A Nobel Prize in Physiology or Medicine
for research on the immune system.
How significant is this?
Pretty significant when it comes to, you know,
the thing that's designed to protect us from getting sick.
And of course, for most of us,
it works pretty well, the immune system.
Sometimes, though, it doesn't work
quite the way we want it to.
And people get things called autoimmune disorders.
And we probably know these more commonly
as things like diabetes or Crohn's disease
or rheumatoid arthritis is just a few of many examples.
What this research recognises is understanding,
foundational understanding of how the immune system
sometimes gets the job done
and sometimes isn't able to do so.
In 1995, they discovered that T-cells,
which we already knew about,
were regulated by something that is now called
regulatory T-cells.
Imagine a traffic warden coming in and saying,
okay, these traffic lights are doing their job,
but the traffic lights aren't always doing their job
and I'm gonna fix those ones up.
And in this case, regulatory T-cells
work out which immune cells aren't working
and doing their job and gets them out of that situation.
The other part of the research was to actually understand
why that process is sometimes not working.
And that is to say, there's a mutation on a particular gene
and if that exists in some people,
maybe these regulatory T-cells aren't able to function
the way that we need them to.
So ultimately, it's an understanding
or recognition of the understanding
that this is how our immune system
is able to work effectively,
the cells that are involved in that process
and why sometimes they don't work.
So if we have a better understanding
of why the immune system sometimes breaks down
and attacks itself,
what does it mean for people
with these autoimmune diseases?
Like you said, people with Crohn's disease,
multiple sclerosis, I mean, can they look forward
to a future with perhaps better treatments or even a cure?
I think that's the question
that everyone is asking, isn't it?
And the answer probably in this case is a cautious yes.
As I say, it's foundational.
So we're recognising the achievement
and the discovery of how these things work.
The next question is, can we translate that
into something that works for people?
There are about 200 or so clinical trials underway
into various drugs and therapies
that might help fix these malfunctioning
regulatory T-cell processes
in people that need it to be fixed.
But they haven't gone to producing these drugs
and for many of these clinical trials,
they're coming back negative.
We're not actually able to say
this is advancing us in the direction we want.
So the promises in what could happen in the future,
recognising it's taken 30 years
for us to recognise these discoveries,
it could take 20 to 30 years more
for us to actually get something people can use.
That's a long time and we hear all the time
how difficult it is to get animals to do these testing,
to get people to do these testing.
At the same time, we're hearing that AI
is going to change everything
and that we're gonna be able to have,
I guess, individually designed,
genetically designed treatments, but we're not there yet.
That makes me wonder, the Nobel Prize for in medicine,
how relevant is it really now?
I think it's always an interesting question to ask.
We've got all these prizes
that recognise scientific achievements.
The Nobel Prizes are right at the top
and tomorrow we'll recognise a physics recipient
and chemistry on Wednesday.
What is the significance?
What is the relevance of the Nobel Prize?
It acknowledges the work that,
in this case, three people have done
in terms of discovery and understanding
of this particular field.
Ultimately, these are three people
that are totemic, in a way.
They represent many diverse contributions
across this particular new field, effectively,
that is being recognised today.
Hundreds, thousands of scientists,
all contributing over a very long period of time
to say, this is what we didn't know 30 years ago
and now we actually understand how these things work.
The next step, as I say, is to translate that.
The Nobel Prize is really that opportunity to recognise
for three people with a cash prize as well
what that achievement is.
All right, our science reporter, Matthew Ward-Ages.
Matthew, good to have you in the studio.
Thank you.
